Publications in collaboration with researchers from Pfizer (United States) (7)

2021

  1. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain

    Mycoses, Vol. 64, Núm. 1, pp. 66-77

2017

  1. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in spain

    ClinicoEconomics and Outcomes Research, Vol. 9, pp. 39-47

2016

  1. La evaluacion de factores de riesgo y el asesoramiento durante 12 meses reduce el riesgo metabolico y cardiovascular en pacientes con trastornos del espectro esquizofrenico con sobrepeso u obesidad: Estudio CRESSOB

    Actas Espanolas de Psiquiatria, Vol. 44, Núm. 1, pp. 20-29

2014

  1. Prevalence of Metabolic Syndrome in Spanish patients with schizophrenia and overweight. The CRESSOB study

    Actas Espanolas de Psiquiatria, Vol. 42, Núm. 1, pp. 9-17

2007

  1. Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the ZEUS longitudinal study Ziprasidone Extended Use in Schizphrenia (ZEUS)

    Actas Espanolas de Psiquiatria, Vol. 35, Núm. 4, pp. 259-262

2006

  1. Cost-effectiveness analysis of schizophrenia relapse prevention: An economic evaluation of the ZEUS (Ziprasidone-Extended-Use-in-Schizophrenia) study in Spain

    Clinical Drug Investigation, Vol. 26, Núm. 8, pp. 447-457

2005

  1. Ziprasidone: From pharmacology to the clinical practice. One year of experience

    Actas Espanolas de Psiquiatria, Vol. 33, Núm. 5, pp. 311-324